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Summary
Glioblastoma (GBM) is the most frequent and aggressive type of brain tumor. There are limited therapeutic options for GBM so
that new and effective agents are urgently needed. Euphol is a tetracyclic triterpene alcohol, and it is the main constituent of the
sap of the medicinal plant Euphorbia tirucalli. We previously identified anti-cancer activity in euphol based on the cytotoxicity
screening of 73 human cancer cells. We now expand the toxicological screening of the inhibitory effect and bioactivity of euphol
using two additional glioma primary cultures. Euphol exposure showed similar cytotoxicity against primary glioma cultures
compared to commercial glioma cells. Euphol has concentration-dependent cytotoxic effects on cancer cell lines, with more than
a five-fold difference in the IC50 values in some cell lines. Euphol treatment had a higher selective cytotoxicity index (0.64–3.36)
than temozolomide (0.11–1.13) and reduced both proliferation and cell motility. However, no effect was found on cell cycle
distribution, invasion and colony formation. Importantly, the expression of the autophagy-associated protein LC3-II and acidic
vesicular organelle formation were markedly increased, with Bafilomycin A1 potentiating cytotoxicity. Finally, euphol also
exhibited antitumoral and antiangiogenic activity in vivo, using the chicken chorioallantoic membrane assay, with synergistic
temozolomide interactions in most cell lines. In conclusion, euphol exerted in vitro and in vivo cytotoxicity against glioma cells,
through several cancer pathways, including the activation of autophagy-associated cell death. These findings provide experi-
mental support for further development of euphol as a novel therapeutic agent for GBM, either alone or in combination
chemotherapy.
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Introduction
Gliomas account for more than 70% of central nervous system
(CNS) tumors. They are the second most frequent pediatric
tumor in the world and therefore considered a major public
health problem [1, 2]. Glioblastoma (GBM) is classified by
the World Health Organization as a grade IV tumor, and it is
biologically the most aggressive of the gliomas. GBM is the
most frequent glioma subtype accounting for about 65% of
cases [2–4] and the tumor may manifest at any age, but typi-
cally has a peak incidence of between 45 to 75 years of age
[5–7]. GBMs are lethal tumors, with a median survival of
about 14 months with less than 10% of patients surviving
for two years following diagnosis (http://www.cancer.org;
http://www.cbtrus.org) [3, 8].
The aggressive behavior of GBMs is in part due to a com-
bination of intense cellular proliferation, diffuse infiltration,
increased resistance to cell death, and high levels of angiogen-
esis [9, 10]. Thus, in addition therapy for GBM includes a
combination regimen of radiotherapy and adjuvant chemo-
therapy with temozolomide (TMZ) [8]. Despite this multi-
modal approach, GBM usually responds poorly and prognosis
has only slightly improved with time [3, 8]. Therefore, re-
search and development of new sources of drugs with prom-
ising therapeutic findings and fewer side effects are urgently
needed for GBMs.
Bioactive plants or their extracts are rapidly emerging as an
alternative source of novel anti-cancer drugs. Importantly, nat-
ural products can have high antitumoral efficiency without
some of the harmful side effects of conventional chemother-
apies [11]. An example is resveratrol (3,4,5-trihydroxy-trans-
stilbene) is a polyphenolic phytoalexin widely present in
plants [12]. This compound exerts beneficial functions in nor-
mal cells and has been reported to be cytotoxic for the major-
ity of malignant cells, blocking some stages of carcinogenesis
in several types of cancer cells and models, including GBM
[12–14].
Traditional healers use extracts of plant species from the
genus Euphorbia (Euphorbiaceae) for the treatment of ulcers,
warts, cancer and other diseases. For instance, euphol is a
tetracyclic triterpene alcohol and the main constituent found
in the sap of E. tirucalli, showing anti-inflammatory, antiviral
activities, analgesic effect as well as antinociceptive properties
[15–18]. Some plants of this family have also been tested for
their antineoplastic activity; however, the biological impact
has not been well explored, with some reports in breast and
gastric tumor cell lines, which showed that euphol could de-
crease cell viability [19, 20].
In a previous study, we assessed the antineoplastic potential
of euphol in a large panel of commercial cancer cell lines,
including glioma cell lines [15]. We found that euphol has a
promising cytotoxicity effect against several cancer cell lines,
and significantly inhibited cell motility and migration,
proliferation, and anchorage-independent growth of pancreat-
ic cancer cell lines [15]. However, to the best of our knowl-
edge, no studies have reported the mechanism of euphol ac-
tion and its biological effect in gliomas.
Therefore, in the present study, we expanded our previous
toxicological screening by investigating the therapeutic poten-
tial of euphol on primary glioma cells and by analyzing the
signaling pathways and the specific cellular effects of the
drug.
Material and methods
Cell lines and cell culture
Twelve immortalized human cell lines, comprising seven
adult and five pediatric glioma cells lines, two primary cul-
tures and one normal human astrocyte were used to perform
cytotoxic assays. All the cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM 1×, high glu-
cose; Gibco, Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Gibco, Invitrogen) and 1% penicillin/
streptomycin solution (Gibco, Invitrogen), at 37 °C and 5%
CO2. Conditions and cell line origins are indicated in
Supplementary Table 1. Additionally, two primary tumor cell
lines, HCB2, and HCB149, derived from surgical glioblasto-
ma biopsies obtained at the Neurosurgery Department of the
Barretos Cancer Hospital (São Paulo, Brazil) were used [21,
22]. The local ethics committee approved the study protocol,
and patients signed an informed consent form. The isolated
cells were grown in DMEM medium under the same condi-
tions described above. Authentication of all cell lines was
carried out by the Diagnostics Laboratory at the Barretos
Cancer Hospital (São Paulo, Brazil) as reported [15, 23].
Identification of the established primary culture confirmed
that both primary culture and blood derived from the same
patient.
Preparation and compound dilution
The euphol purification process, biochemical characterization,
and dilution were carried out as described previously [15, 24].
The chemical structure of the euphol, represented in Fig. 1a
was determined by elemental analyses of 1H NMR and 13C
NMR spectral data, and by comparison with their respective
authentic compounds using ChemDraw software version 7.0
[24] (PubChem CID: 441678). The tetracyclic triterpene
euphol used in this study showed >95% purity. The drug
euphol was provided by Amazônia Fitomedicamentos Ltda,
which is the sole and exclusive owner of the respective intel-
lectual property rights.
The extract fractionwas initially dissolved in dimethyl sulf-
oxide (DMSO) at a concentration of 50 mg/mL and stored at
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−20 °C. The intermediate dilutions of the experimental com-
pound were prepared to obtain a concentration of 1% DMSO.
Cell viability and proliferation assay
The cytotoxicity effect of euphol was assessed byCell Titer 96
Aqueous cell proliferation assay (MTS assay-PROMEGA),
and the proliferation effect was evaluated by ELISA-BrdU
assay (Roche Applied Science, Mannheim, Germany), fol-
lowing the manufacturer’s instructions as previously de-
scribed [15, 23]. Cells were plated into 96-well plates (until
a maximum 5 × 103 cells/well) and treated with increasing
concentrations of the euphol diluted in DMEM (0.5% FBS)
or vehicle (1% DMSO, final concentration) for 72 h. Half-
maximal inhibitory concentration (IC50) data were evaluated
using the non-linear regression curve using GraphPad PRISM
version 5 (GraphPad Software, La Jolla California USA), as
previously determined [15, 23]. Also, the proliferation effect
was assessed two hours before the end of incubation by
ELISA-BrdU assay kit (Roche, Applied Science, Mannheim,
Germany) following the manufacturer’s instructions.
Moreover, in our screening, we adopted the criteria of
growth inhibition (GI) to allow classifying the cell line
profiles [25]. GI was calculated as a percentage of untreated
controls, and its values were determined at a fixed dose of
15 μM (concentration that corresponds approximately to the
average IC50 value of all cell lines at screening). Samples
exhibiting more than 60% growth inhibition in the presence
of 15 μM euphol were classified as highly sensitive (HS); as
resistant when showing less than 40%; and as moderately
sensitive (MS) when showing between 40 and 60% growing
inhibition. All the assays were done in triplicate and repeated
at least three times.
Selectivity index (SI)
The selectivity index for the cytoxicity of euphol was
expressed as the ratio between the IC50 value on the normal
human astrocyte cell line (NHA) and the IC50 value on each
cancer cell line (SI=IC50 normal cell/IC50 cancer cell). Values
greater than or equal to 2.0 are considered to be an important
selectivity index [26].
Wound healing migration and invasion assay
Cell migration properties of GAMG, and U373 cell lines were
evaluated by wound healing assay as previously described by
our group [21]. The images shown are representative of three
independent experiments performed in triplicates.Cell invasion
assay in GAMG and U373 cells was performed using 24-well
BD Biocoat Matrigel Invasion Chambers, according to the
manufacturer’s instructions (354,480, BD Biosciences) [21].
Cell cycle and apoptosis assays
Cell cycle and apoptosis assays were assessed by flow
cytometry as previously described [27]. In brief, the cells
were plated onto a six-well plate at a density of 1 × 106
cells/ well, allowed to adhere for at least 24 h and serum
starved for 12 h. Additionally, the cells were exposed to
IC50 concentrations values of euphol for a period of 6, 24,
48 and 72 h in DMEM (0.5% FBS). The cell cycle distri-
bution (G1, S, and G2/M) as well as double staining with
Annexin V-FITC and PI for apoptosis analysis were de-
termined with a flow cytometer BD FACSCanto II (BD
Biosciences) and analyzed with the software BD
FACSDiva (BD Biosciences) following the manufacturer’s
recommended protocol. Approximately, 2 × 104 cells were
evaluated for each sample in both assays.
Proteome arrays
Relative protein expression levels of a panel of 35 proteins
related to apoptosis and 26 proteins related to cellular stress
were obtained using the Proteome Profiler Human Apoptosis
Array Kit #ARY009 (R&DSystems) and Proteome Profiler
Fig. 1 Effect of euphol on cell viability of commercial and glioma
primary culture. a Euphol chemical structure. b Cytotoxicity profile of
14 human glioma cell lines, exposed to euphol compound. Bars represent
the cell viabillity at 15 μM of euphol. Colors represent the GI score
classification and cancer cell lines sbgroups. Gray (HS = Highly
sensitive); Blue (MS =Moderate Sensitive); Red (R = Resistant); Black
(Adult glioma cell line); Orange (Pediatric glioma cell line) and Green
(glioma primary culture)
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Human Cell Stress Array Kit #ARY018 (R&DSystems), ac-
cording to the manufacturer’s instructions and as previously
reported [21]. The selected cell lines were treated with euphol
for 6 and 24 h using a concentration equivalent to an IC50
value of each cell line. After treatment the cells were prepared
as previously described for western-blot analysis [21].
Aliquots of 500 μg of total protein were used for apoptosis
proteome profile and stress human cell arrays (R&D Systems)
following manufacturer’s instructions.
Western blotting
To evaluate the expression of altered proteins following
euphol treatment, the cells were plated onto a six-well
plate at a density of 1 × 106 cells/well, allowed to adhere
at least 24 h, and were serum-starved in DMEM (0.5%
FBS). The cells were exposed at IC50 concentration
values of euphol for an additional period of 6, 24, 48
and 72 h in DMEM (0.5% FBS). After the cells were
prepared and aliquots of 20 μg of total protein were sep-
arated as previously described for western-blot analysis
[27]. Antibodies included anti-Bip, Rip, p-27, DR5,
SOD2, CytC, pP53 (S15), HSP60, HSP70, FADD and
β-tubulin, all antibodies were diluted at 1:1000, (Cell
Signalling Technology). In addition to PKC profile anal-
ysis, antibodies included total PKCs (PKCα, PKCδ and
PKCζ), and phosphorylated PKCs; p-PKC PKDμ (S916),
p-PKC PKDμ (S744), p-PKCα/βII, p-PKCpanβII,
p-PKCδ, p-PKCδ/θ, p-PKCθ and PKCζ/λ, all antibodies
were diluted at 1:1000 and purchased from Cell
Signalling Technology.
Analysis of the autophagy process in tumor cell lines
treated with euphol
The cells were plated onto a six-well plate at a density of 1 ×
106 cells/ well, and allowed to adhere for at least 24 h. The
growth medium was replaced by Hanks balanced salt solution
(HBSS; Invitrogen) for starving the cells (two rinses in HBSS
before being placed in HBSS). Then, the cells were treated
with 10 nM (GAMG) and 20 nM (U373) of bafilomycin A1
(Baf), to inhibit autophagy [28]; or with euphol, using a con-
centration equivalent to IC50 of the evaluated cell line; or with
a combination of Baf and euphol. All these treatments were
diluted in HBSS. For autophagy assay controls, some cells
were maintained in DMEM alone or treated with euphol di-
luted in DMEM. After 2, 6 or 24 h, the cells were scraped into
cold PBS1X and subjected to western blot analysis as already
described. For this, we used the primary polyclonal antibodies
LC3A/B (dilution 1:1000; Cell signaling) and β-tubulin (di-
lution 1:5000; Cell Signaling Technology), as a loading
control.
Detection and quantification of acidic vesicular
organelles (AVOs) with acridine orange
To detect and quantify the AVO in euphol-treated cells,
we performed the vital staining with acridine orange as
reported [28]. The assay was performed according to the
conditions for autophagy analysis as mentioned previous-
ly. Subsequently, 72 h after exposure to euphol, cells were
removed from the plate with trypsin (Gibco, Invitrogen)
and stained with acridine orange at a final concentration
of 1 μg/mL for 15 min, and washed twice in PBS 1X.
Green (510–530 nm) and red (>650 nm) fluorescence
emission from 104 cells illuminated with blue (488 nm)
excitation light were measured with a flow cytometer BD
FACSCanto II (BD Biosciences) and analyzed in software
BD FACSDiva (BD Biosciences). FITC-A emits green
fluorescence, while PerCP-A emits red fluorescence.
These analyses were performed in experimental and bio-
logical triplicates.
Analysis of the effect of the autophagy inhibitor,
bafilomycin A1 (Baf), on tumor cell lines combined
with euphol
To determine the effect of the autophagy inhibitor on cell
viability after treatment with euphol 5 × 103 cells were
plated into 96-well plates in triplicate, and increasing con-
centrations of euphol were added. To inhibit autophagy,
fixed dose of Baf (10 nM for GAMG cells and 20 nM for
U373 cells) was added to the culture 3 h after euphol
treatment. The cell viability assay was evaluated after
72 h using the Cell Titer 96 Aqueous test One Solution
Cell Proliferation Assay (Promega), as described by the
manufacturer. Absorbance was measured on an ELISA
plate (VarioskanTM-Flash, Thermo Scientific) reader at
490 nm. The data were obtained, and normalized relative
to the average survival of untreated samples, or only treat-
ed with Baf. The analyses were performed in experimental
and biological triplicates.
Colony formation- assay
Inhibiting anchorage-independent growth was performed
using a soft-type-agar assay as previously reported [15]. We
used 2 × 104 cells of GAMG and U373. The medium was
changed every two days, and DMEM +0.5% FBS containing
euphol at 8 and 30 μM was added. Colonies formed were
stained with 0.05% crystal violet for 15 min. Photo-
documented colonies were analyzed using the Image J
Software. The assay was performed in two biological repli-
cates, and the experiments were done in duplicate.
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Chicken chorioallantoic membrane (CAM) assay
In vivo tumor proliferation of U373 and GAMG cell lines was
assessed by CAM assay, as previously described [21, 29].
Fertilized chicken eggs were maintained at 37 °C to allow
their development. On the third day, a window was made into
the eggshell, allowing access to the CAM. On the tenth day of
development, a small plastic ring was placed on the CAM, and
2 × 106 cells (in 20 μL DMEM- serum-free medium- Gibco
Invitrogen) from U373 and GAMG cell lines were inoculated
therein. The eggs were tapped and incubated. On the four-
teenth day, the ring with cells was photographed in ovo using
a stereomicroscope (Olympus S2 × 16) and a digital camera
(Olympus DP71). Next, 20 μL of 0.5% FBS culture medium
containing euphol (IC50 value) or vehicle control were
injected over the tumors. On day 17 (72 h of incubation with
the drug), the tumors were again photographed in ovo. The
chickens were sacrificed by a stay at −80 °C for 10 min, and
the tumors or CAM alone were fixed with 4% paraformalde-
hyde and photographed ex ovo. The perimeter of the tumors
was measured using the Cell B software (Olympus) in ovo at
days 14 and 17. The results were expressed as mean percent-
age of tumor growth for each group, from day 14 (considered
as 0%) to day 17, ± SD. For blood vessel counting, photo-
graphs were taken at day 17 ex ovo, and the results were
expressed as the mean of the vessels counted manually for
each group of treatments ± SD. All procedures performed in
studies involving animals were in accordance with the ethical
standards of the institution or practice at which the studies
were conducted.
Drug combination studies
Combination studies were done with fixed concentrations (de-
termined IC50 value) of standard chemotherapeutic (temozo-
lomide - Sigma - T2577), exposed to increasing concentra-
tions of euphol. The results were expressed as mean viable
cells relatively to the conditions of the fixed drug alone (con-
sidered as 100% viability) ± SD. The drug interactions were
evaluated by the combination index (CI) using CalcuSyn soft-
ware version 2.0 (Biosoft; Ferguson, MO, USA) [30, 31]. In
CI analysis, synergy was defined as CI values significantly
lower than 1.0; antagonism as CI values significantly higher
than 1.0; and additivity as CI values equal to 1.0 at drug IC50
value for each cell line.
Statistical analysis
The results of in vitro and in vivo experiments are expressed
as the mean ± standard deviation (SD) of three independent
experiments and differences with p < 0.05 on the Student’s t-
test were considered statistically significant. All analyses were
performed using the aforementioned GraphPad PRISM ver-
sion 7 (GraphPad Software, La Jolla, CA, USA).
Results
Euphol promotes cytotoxicity and selectivity
on glioma cell lines and potentiates
temozolomide-induced decrease in cell viability
The antitumor effect of euphol in vitro was assessed by MTS
assay in 12 glioma cell lines from commercial (adult and pe-
diatric), primary cultures, and from one normal immortalized
astrocytic cell line (Table 1). For this active extract, we gen-
erated complete dose-response curves, and calculated the IC50
values. There was a heterogeneous profile of response to
euphol with each cell line exhibiting a distinct treatment re-
sponse. The mean of IC50 values was 19.38 μM, but varied
significantly between individual cell lines, with more than a
five-fold difference in the IC50 values (IC50 range: 5.98–
31.05 μM) (Table 1).
Pediatric glioma cell lines showed the most sensitive pro-
file in comparison to primary cultures and adult glioma cell
lines (IC50 mean 13.6, 15.3 and 24.1 μM, respectively). To a
better classify the response to euphol, we adopted the criteria
of growth inhibition (GI) at a fixed dose of 15 μM. This
concentration was chosen because it closely corresponds to
the average IC50 value of all cell lines at initial screening. At
this fixed dose, we found that 50% (7/14) of cell lines were
resistant, 28.5% (4/14) were moderately sensitive, and 21.4%
(3/14) were classified as highly sensitive (Fig. 1b and Table 1).
Moreover, euphol had a higher selective cytoxicity index
(0.64–3.36) than TMZ (0.11 to 1.13) (Table 1).
When combined, euphol and TMZ treatments seem to have
a synergistic effect (combination index (CI < 1) in 67% (8/12)
of the glioma commercial cells lines investigated (mean CI
values: range: 0.48–0.96) (Table 1).
Biological effect of euphol on glioma cell lines
Euphol inhibits proliferation and migration but does not
impair invasion and colonies formation on glioma cells
To further explore the biological role of euphol in glioma cells,
we investigated the effect of euphol selecting one drug-
sensitive cell line (GAMG) and one drug-resistant cell line
(U373) (Table 1). To determine whether euphol had cytotoxic
or cytostatic effects on glioma cells we treated the cell lines
with various concentrations of euphol for 72 h, and measured
proliferation levels by BrdU incorporation. Overall, euphol ex-
hibited dose-dependent proliferation and cytotoxicity effects on
glioma cells (data not shown). The fixed dose of 15 μM of
euphol inhibited 35.44% of the proliferation in GAMG and
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28.71% in U373 cells (Fig. 2a). Although euphol decreased the
proliferation of GAMG and U373 cells, the strongest inhibition
was seen at the highest applied dose of euphol (data not
shown). Moreover, at 15 μM euphol suppressed cell viability
of GAMG cells by 88.86% and U373 cells by 13.9% (Fig. 2b).
Thus, these data suggest that euphol seems to have predomi-
nantly cytotoxic effects on the anchorage-dependent growth of
both malignant glioma cell lines.
Next, the impact of euphol on cellular migration was eval-
uated, and no significant effect was observed in GAMG cells,
suggesting that euphol (8 μM - IC50 value) has moderate or no
interference on their migratory capacity (Fig. 2c). However,
euphol (30 μM - IC50 value) considerably reduced U373 cell
migration ability at 48 and 72 h compared to untreated cells
(Fig. 2d). In the GAMG cells a further 72 h were required for
the wound to completely close in untreated conditions (data
not shown), suggesting that these cell have an intrinsic low
capacity for migration and this may be why euphol has less
effect on GAMG cells than the resistant cell line (U373).
The ability of euphol to inhibit cell invasion and
anchorage-independent growth was also assessed. Euphol (8
and 30 μM) did not inhibit cell invasion (Supplementary Fig.
1a, b) nor did it suppress colonies number or size in either of
the glioma cell lines (Supplementary Fig. 1c, d).
Glioma cells do not undergo cell growth arrest and apoptosis
upon euphol exposure
To understand the biological mechanism of euphol on cell
cycle and apoptosis, we assessed changes in signaling proteins
using a human apoptosis and cell stress proteome array, com-
prising 61 proteins related to apoptosis, cell cycle and stress
signaling (listed in Supplementary Fig. 2a, b). As shown in
Fig. 3a and Supplementary Fig. 2a, the cell stress proteome
array assay revealed that the exposure of GAMG cells (drug-
sensitive) to euphol at 6 h resulted in downregulation of the
majority of the proteins in response to euphol, with the single
exception of upregulation in SOD2. In contrast, in the drug-
resistant cells (U373), we observed a marked reduction in
BCl-2 and NF-κB1 expression and minor changes in other
proteins such as HSP60 and HIF1. Remarkably, euphol in-
creased levels of SOD2, Thioredoxin-1 and P21 CIP1 (Fig.
3a and Supplementary Fig. 2d). However, GAMG cells treat-
ed with euphol only had upregulation of P53 (S15) activation
Table 1 The euphol half maximal inhibitory concentration (IC50), percentual growth inhibition (GI), the selectivity index (SI) and Combination Index
(CI) of euphol against the glioma cell lines
Cell line Euphol
IC50 ± S.D. (μM)
Growth
inhibition*
Growth
inhibition
score
TMZ
IC50 ± S.D.
(μM)
Euphol
SI**
TMZ
SI**
Combination
Index (CI)***
T M Z +
euphol
Primary histology
U87-MG 26.41 ± 3.19 6.7 ± 12.7 R 746.76 ± 3.15 0.76 0.15 1.11 Adult Glioma
U373 30.48 ± 3.51 10.0 ± 12.1 R 544.75 ± 1.53 0.66 0.20 0.48
U251 29.01 ± 7.82 23.3 ± 9.5 R 696.40 ± 2.92 0.69 0.16 0.95
GAMG 8.73 ± 1.87 90.1 ± 0.5 HS 97.00 ± 2.05 2.30 1.13 1.95
SW1088 27.12 ± 2.55 7.2 ± 7.2 R 979.2 ± 4.00 0.74 0.11 0.70
SW1783 19.62 ± 1.42 44.2 ± 9.6 MS >1000± 1.02 UD 0.94
SNB19 31.05 ± 5.85 12.6 ± 20.5 R >1000± 0.64 UD 0.67
RES186 16.70 ± 3.72 41.6 ± 14.8 MS 714.75 ± 7.08 1.20 0.15 1.34 Pediatric Glioma
RES259 10.34 ± 4.08 70.6 ± 8.6 HS 206.05 ± 6.09 1.94 0.53 0.52
KNS42 19.94 ± 0.27 23.3 ± 6.2 R >1000± 1.01 UD 1.10
UW479 15.26 ± 4.83 53.4 ± 15.3 MS >1000± 1.31 UD 0.92
SF188 5.98 ± 2.42 74.4 ± 4.3 HS >1000± 3.36 UD 0.96
HCB2 11.66 ± 1.14 59.1 ± 4.0 MS ND 1.72 ND ND Primary Glioma
HCB149 21.68 ± 5.60 23.5 ± 7.0 R ND 0.92 ND ND
NHA 20.14 ± 4.16 47.2 ± 3.6 MS 110.5 ± 1.05 Normal Human
Astrocytes
*GI was calculated as a percentage of untreated controls, and its values were determined at a fixed dose of 15 μM. Samples exhibiting more than 60%
growth inhibition in the presence of 15 μM euphol were classified as highly sensitive (HS); as resistant when showing less than 40%; and as moderately
sensitive (MS) when showing between 40 and 60% growing inhibition
**The selectivity index (SI) is the ratio between the IC50 values for NHA (Euphol IC50 = 20.14 ± 4.16 μM and TMZ IC50 = 110.5 ± 1.05 μM) and those
for the glioma cell lines. UD = undetermined (>1000 μM); ND = not determined
***The CI was analyzed using CalcuSyn Software version 2.0. The CI value significantly lower than 1.0, indicates drug synergism; CI value
significantly higher than 1.0, drug antagonism; and CI value equal to 1.0, additive effect
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and minor activation of P53 (S46) after 24 h (Fig. 3b and
Supplementary Fig. 2b). In addition, euphol treatment de-
creased the expression of several proteins, especially: XIAP,
Trail R1/DR4, Trail R1/DR5, BCL-X, and BAX while other
proteins showed unchanged expression (Fig. 3b). The protein
expression levels were also mostly influenced by euphol in
drug-resistant cells at 24 h. Marked activation of P53 (S15),
and P53 (S46) was also clearly observed in drug-resistant cells
as well as upregulation of Trail R1/DR5, HSP60, and HSP70.
Similarly to GAMG cells, the protein expression levels of
CLASPIN, CATALASE, HIF-1, FASTNFR6/CD95 and
TNRI/TNFRSF1A were particularly downregulated in U373
(Fig. 3b). These results suggest that euphol could modulate
the protein profile in glioma cell lines in distinct ways.
We further examined the cell cycle distribution. FACS
scanning after euphol treatment (8 and 30 μM, 72 h), showed
that the cell cycle distribution (G1, S, and G2/M) of GAMG
(data not shown) and U373 cells were not significantly affect-
ed (Supplementary Fig. 3a). Similarly, euphol did not appear
to affect apoptosis in either GAMG or U373 cells using the
same concentrations of euphol treatment evaluated by
AnnexinV-FITC /PI (Supplementary Fig. 3b).
Fig. 2 Effect of euphol on glioma cell proliferation and cytotoxicity. a
Cell proliferation and b) cell viability were measured with BrdU and
MTS assay, respectively, after 72 h of euphol treatment. The
proliferation of the untreated cells = 100%. Results shown are the
means ± S.D. of three independent experiments. c GAMG and d) U373
cells were seeded and grown in 0.5% FBS medium containing euphol (8
and 30 μM, respectively) and evaluated by wound healing assay
migration assay. A standardized scratch (wound) was applied to
monolayers, and digital images were taken at several time points (0, 24,
48 and 72 h) in the same area. The distances in pixels were calculated and
the percentage was calculated in time 0 h. The figures are representative
of three independent experiments
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Euphol induces autophagy in glioma cells
We next determined whether euphol could regulate autophagy
cell death mechanisms, by examining the expression of the
autophagy-associated protein LC3-II. Exposure to euphol (8
and 30μMeuphol) for 2 and 6 h, GAMG and U373 cells were
collected and evaluated by western blotting. GAMG cells ex-
hibited a marked increase of LC3-II compared to untreated
control cells after euphol treatment either alone or when com-
bined with Baf (Fig. 4a, b). Expression of LC3-II was espe-
cially evident following 2 h (2–fold increase) treatment. There
was also significant autophagy in U373 cells treated with
euphol for 2 h (data not shown). To characterize autophagy
further, we performed flow cytometry after staining cells with
acridine orange, a dye that detects the lysosomotropic alter-
ations associated with acidic vesicular organelles (AVOs).
Euphol treatment led to a marked increased in the acridine
orange bright red fluorescence (y-axis) in U373 cells from
15.5–43.8% compared to control, indicating development of
fractional volume and/or acidity of AVOs (Fig. 4c-d). To in-
vestigate euphol-induced AVOs further we performed addi-
tional experiments including the agent Baf, which is a vacuo-
lar type H (+)-ATPase inhibitor that inhibits the fusion be-
tween autophagosome and lysosome [38]. We observed an
increase of AVOs when the cells were treated either with
euphol alone or when combined with Baf (GAMG 10 nM
and U373 20 nM). This combination increased the formation
of AVOs in U373 cells from 25.9 to 66.8% compared to Baf
alone (Fig. 4d). In GAMG cells the effect was less evident
(Fig. 4c). These results suggest that euphol treatment induces
an increase in the development of AVOs, which is possibly
associated with autophagy.
To investigate whether inhibition of autophagy at a late stage
affects the cytotoxicity of euphol, we treated U373 and GAMG
cells with a dose range of euphol for 72 h in the presence of a
fixed dose of Baf that was added 3 h after euphol treatment.
The cell viability of the euphol (350 nM) treated GAMG cells
was reduced from 100 to 45% by Baf, while in U373 the cell
viability was reduced from 100 to 30% with euphol (5.85 μM)
Fig. 3 Effect of euphol on cell stress and apoptosis cell in glioma cell
lines. a Panel of 26 proteins related to cellular stress and b 35 proteins
related to apoptosis. The data represented by the heat maps show the
proteins modulated after 6 h (panel of cellular stress) and 24 h (panel of
apoptosis) of euphol treatment (3X IC50 value) in glioma cells, GAMG
and U373. The quantification and normalization of proteins was
performed using the positive controls and untreated controls from the
package Protein Array Analyzer of Image J software
Fig. 4 Euphol induces autophagy in glioma. a) Cells were treated with
IC50 concentrations of euphol for the indicated time periods. GAMG cell
lysates (20 μg per lane) were analyzed using immunoblotting with anti-
LC3. a and (b) are GAMG representative of three independent
experiments. Tubulin was used as an internal control to normalize the
amount of proteins applied in each lane. Development of AVO in
Euphol-treated cells by detection of green and red fluorescence in
acridine orange-stained cells using FACS analysis. c GAMG and d)
U373 were treated with euphol (8 and 30 μM, respectively), and
bafilomycin A1 (Baf) (GAMG 10 nM and U373 20 nM) for 72 h. The
graphs are representative of at least two independent experiments. FITC
indicates green fluorescence, while PerCP shows red fluorescence. Effect
of Baf on the cell viability of euphol-treated cells. eGAMG f) U373 cells.
At 3 h after exposure to euphol, baf was added and cultured until 72 h and
evaluated by MTS assay. The viability of the untreated cells =100%.
Results shown are the means ± S.D. of three independent experiments.
Effect of Baf on euphol-induced apoptosis. After the euphol and
bafilomicyn treatment for 72 h, GAMG (g) andU373 (h) cells were fixed,
stained with annexinV-FITC /PI -PE and analyzed by FACScan. Data
shown are representative of three independent experiments. Baf =
bafilomycin A1
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(Fig. 4e, f). We also investigated whether the decreased cell
viability promoted by Baf in euphol treated cells was due to
induction of apoptosis. However, we found that in Baf pres-
ence, euphol did not induce apoptosis (Fig. 4g, h).
Activation of the PKC signaling pathway by euphol in glioma
cells
The anti-inflammatory effect of euphol in mouse skin has
related to the direct inhibition of PKCα [32]. To investigate
the possible role of PKC activity after treating glioma cells
with euphol, we evaluated the PKC isotypes activation profile
using immunoblotting. In these experiments we detected the
conventional PKCs (cPKCs): PKCα, p-PKCα/βII, p-
PKCpanβII, novel PKCs (nPKCs): PKCδ, p-PKCδ, p-
PKCδ/θ, p-PKCθ, and atypical PKCs (aPKCs): p-PKCζ/λ,
PKCζ as well as PKD1/PKCμ, p-PKC PKD (S916), and p-
PKC PKDμ (S744), and no changes were observed in the
status of the majority of total or phosphorylated PKC isotypes,
in either of the malignant glioma cells. However, our data
demonstrated that the activation of PKC/PKDμ isotypes was
markedly inhibited by euphol in Ser744 and especially, in
Ser916 residues during all kinetic evaluated in the U373 cells
(Fig. 5b). In contrast, euphol treatment of drug-resistant U373
cells did not seem to affect PKC/PKDμ isotypes (Fig. 5a).
Effect of euphol in vivo by CAM assay
To evaluate the effect of euphol on tumor growth and angio-
genesis in vivo, we performed the CAM assay. The mean
perimeters of the tumors formed in the control (DMSO) and
the euphol-treated cells were 1500.5 ± 265.3 μm and 1600 ±
50.4 μm, respectively, with no statistically significant differ-
ences observed in the U373 cell line (Supplementary Fig. 4).
However, in euphol treated GAMG cells (n = 19) the mean
perimeter of the tumors was reduced from 2000 μm ±
15.1 μm to 1550 ± 30.3 μm in comparison to control cells
(n = 20) (Fig. 6a, b).
To evaluate the impact of euphol on levels of angiogenesis,
we compared the number of vessels formed around the GAMG
tumors in euphol-treated cells in comparison to control treated
tumors. The mean number of vessels was 40 ± 5 for tumors
formed by the control and 29 ± 4 for the euphol-treated
GAMG cells (Fig. 6a, c). The difference in vessel densities
was statistically significant suggesting that euphol treatment
influenced this process. No statistically significant differences
observed in the U373 cell line (Supplementary Fig. 4).
Discussion
The antitumor activity of euphol was recently reported in a
large panel of 73 human cancer cell lines, including several
glioma cell lines [15]. In the present study, we performed a
comprehensive biological analysis of euphol, the main con-
stituent ofE. tirucalli sap, utilizing a panel of glioma cell lines.
The antitumor effect of euphol in vitro was studied in 10
commercial glioma cell lines, two primary cultures and one
normal human primary astrocytic culture. We found that
euphol treatment exhibited dose-dependent cytotoxic effects
on all tested glioma cancer cell lines. In agreement with our
recent study, the IC50 values presented were lower than 30 μg
/mL for 72 h, a criterion adopted by NCI to consider an extract
as promising for preclinical studies (http://www.cancer.gov)
[33]. The mean of IC50 values was 19.38 μM (8.28 μg/mL).
The glioma cell lines exhibited a heterogeneous profile of
response to euphol with each cell line having a distinctive
individual response. We found that 50% (7/14) of cell lines
were resistant, 28.5% (4/14) were moderately sensitive, and
21.4% (3/14) were classified as highly sensitive. Pediatric
glioma cell lines showed the most sensitive profile compared
to primary cultures and adult glioma cell lines. This variation
in response to euphol is likely a reflection of the intrinsic
differences in the molecular biology underlying pediatric
and adult malignant glioma [34]. The use of primary culture
models for preclinical assays has recently become popular
because these systems appear to mimic the genomic
heterogeneity present in individual tumors [22]. In this
context, our study provides additional support for the need
to characterize and test new drugs using different model
systems that faithfully represent tumor diversity [35].
Importantly, the euphol selectivity indexes were greater
than those observed for the TMZ. Several studies have con-
sidered that a value greater than or equal to 2.0 is a selec-
tivity index worthy of further investigation [26]. This value
means that the euphol has more than twice the cytotoxicity
to the tumor cell lines compared to the normal cell line for
GAMG and SF188 cells, suggesting this compound is safe
for further studies as a promising new therapeutic. In addi-
tion, it was not possible to calculate the selective cytotox-
icity indexes for the majority of the cancer cell lines treated
with TMZ since the drug is more cytotoxic to the normal
reference astrocytic cell line.
Our study showed that euphol inhibition of glioma cell
proliferation was concentration-dependent. Moreover, the in-
creasing loss of cell viability at inhibitory growth concentra-
tions suggests that its effects are more likely to be through
cytotoxicity rather than a cytostatic mechanism. Our results
are in agreement with our previous study [15] and with an
earlier report, which also demonstrated euphol cytotoxicity
in gastric cancer cell lines [20]. However, our results with
glioma cells provide different findings to an earlier study
using breast cancer cells [36], in which euphol was considered
to modulate cell cycle proteins with cytostatic effects. Such
inconsistencies may reflect the underlying biological variation
of euphol in different tumor types.
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We further demonstrated that euphol inhibited cellular mi-
gration in U373, but not in GAMG cells. Euphol was not able
to inhibit cell invasion in either of the glioma cell line
analysed. Moreover, no significant effect was observed in
the suppression of number and size of colonies with euphol
treatment in either of the tested cell lines. There are currently
no reports in the literature describing the biological effects of
euphol on cancer processes such as migration and invasion,
with the single exception of our study on pancreatic cancer
cells [15]. These data suggest that the migration-inhibiting
potential may be part of the general anti-cancer mechanism
of euphol in tumorigenesis.
Next, we evaluated some of the intracellular pathways reg-
ulated by short-term exposure to euphol in glioma cells.
Surprisingly, the protein expression levels in both panels of
proteome arrays were the most modulated in drug-resistant
cell line, U373. Moreover, we found that euphol promoted
changes in anti-apoptotic and pro-apoptotic protein expression
consistent with flow cytometry studies, showing that modula-
tion of anti-apoptotic factors was more pronounced. In partic-
ular, reduced levels of pro-apoptotic BAX, BAD, TNRI/
TNFRSF1A, FASTNFR6/CD95 and cleaved caspase-3 were
observed for both malignant glioma cell lines and p27 and
FADD in GAMG cells. In addition, antiapoptotic proteins
including Livin, PON-2 and heat shock proteins were upreg-
ulated in U373 cells, in comparison to cIAP-2, Survivin,
Claspin and p21 in GAMG cells. Lin and coworkers (2012)
[20] observed the upregulation of the pro-apoptotic protein
BAX and downregulation of the prosurvival protein Bcl-2,
causing mitochondrial dysfunction, possibly by caspase-3
Fig. 5 Effect of euphol on PKC isoenzyme profiles in glioma cell lines.
aGAMG and b) U373 cells were incubated with the IC50 for euphol, at 6,
24, 48 and 72 h. Controls were treated with DMSO alone (1%). Whole
cell extracts from the same preparation were subjected to Western
immunoblotting analysis of PKC isoenzyme expressions. Immunoblots
of β-tubulin are shown as an internal control. Results shown are the
means ± S.D. of two independent experiments
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activation. Our data partially corroborate this study, except
that BAX and caspase-3 were downregulated in both glioma
cells, suggesting there may be differences in the ability of
euphol to promote apoptosis in gastric cancer cells. In U373
euphol increased expression of the cyclin-dependent kinase
inhibitors, p21/CIP1/CDKN1A and p27, and promoted
growth arrest 6 h after exposure, with levels reducing after
24 h. In contrast, in drug-sensitive cells these proteins
remained downregulated at both time-points. Wang et al.
(2013) [36] reported that euphol treatment promoted up-
regulation of p21 and p27 in breast cancer cells, while Lin et
al. (2012) [20] found an increase of p27kip1 levels in gastric
cancer cells. These findings agree with our results from drug-
resistant cells; however we did not observe marked cell cycle
arrest by flow cytometry. Collectively, these results suggest
that cell cycle arrest and apoptosis do not contribute to the
antiproliferative and cytotoxicity effects of euphol in malig-
nant glioma cell lines.
The induction of other non-apoptotic mechanisms of cell
death such autophagy can be important for the elimination
of apoptosis-resistant GBM. Our finding of a marked in-
crease of LC3-II in euphol-treated glioma cells together
with the formation of AVOs suggests that non-apoptotic
processes may be activated by this compound. Moreover,
the inhibition of autophagy by Baf potentiated the cytotox-
icity activity of euphol in both tested glioma cell lines. Our
observations are in keeping with the combinatorial effects
of chemotherapeutic agents used in several clinical trials for
various cancer types [19, 28]. We highlight that the appli-
cation of Baf enhanced the antitumor effect of euphol
against malignant glioma cells by the accumulation of au-
tophagic vacuoles, and not by inducing apoptosis. These
results are particularly important for GBM, because of this
tumor has been shown to be more sensitive to agents that
induce autophagy than it is to apoptosis-inducing drugs
[37]. It has also been shown that autophagic structures are
present in gliomas in vivo after treatments [38]. Moreover,
our results agree with other studies, which have used TMZ,
arsenic trioxide and berberine (natural compound) to in-
duce autophagic cell death in malignant glioma cells, and
shown that Baf enhanced the effect of TMZ and arsenic
trioxide, by inducing apoptosis [39, 40]. In summary, these
results suggest that autophagy plays a crucial role in the
antiproliferative mechanism of euphol against glioma cells,
and that inhibiting autophagy will improve the effective-
ness of treatment.
The expression state of several components within the
cell stress pathway was also assessed. Upregulation of the
antioxidant SOD2, superoxide dismutase 2, in both cell
lines should be highlighted, since this enzyme is an impor-
tant defense against oxidative damage [41]. These changes
indicated that euphol could promote oxidative stress by
ROS induction.
Importantly, we also evaluated the isoforms of PKC. This
family of protein kinases has a well-established role in onco-
genesis and is one of the key targets of euphol [17].
Fig. 6 In vivo role of euphol inGAMG cells growth and angiogenesis.
a Representative images (16× magnification) of CAM assay after seven
days of tumor growth in ovo and ex ovo. b Tumor growth was measured
by perimeter (μM) in vivo by CAM assay as described in material and
methods section. c Counting of the blood vessels ex ovo was performed
manually by image J software. The data is represented as the mean ± SD
and differences with p < 0.05 on the Student’s t test were considered
statistically significant
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Interestingly, while there were no changes in both glioma cell
lines either in total PKC levels or in the general phosphoryla-
tion isotypes, our data demonstrated that activation of PKC/
PKDμ isotypes was markedly inhibited by euphol at Ser744
and in U373 cells there was also strong repression at residue
Ser916. Functional studies have described PKD as a potent
promoter of cell growth and proliferation in multiple cellular
systems, suggesting that PKD may possibly contribute to the
cancer phenotype [42]. PKD1 is phophorylated and active in
primary glioblastoma cells and pharmacological inhibition or
silencing of PKD1 by RNA-interference significantly reduced
proliferation rates of glioblastoma cells in vitro [43].
We evaluated the effects of euphol on tumor growth and
angiogenesis using the CAM in vitro assay. In the drug-
sensitive cell line euphol exposure significantly reduced the
mean perimeter of the tumors and number of the tumors ves-
sels compared to the untreated control, whereas no statistically
significance was observed in the drug-resistant cells. One pos-
sible explanation for the behaviour of U373 cells may be that
euphol did not affect angiogenesis in this cell line, which
could have indirectly reduced the supply of oxygen to tumor
cells. Santos et al. (2016) [40] used an in vivo approach based
on the ascitic Ehrlich tumor model to show that treatment with
E. tirucalli hydroalcoholic extract led to increased survival in
mice. These findings indicate the antitumoral and
antiangiogenic activity of euphol in vivo. Therefore, these
studies draw attention to the opportunity of investigating the
effects of euphol on angiogenesis in glioma at different stages
of the disease.
Importantly, we have also shown that the combined admin-
istration of euphol and TMZ exerted synergistic antitumoral
action on malignant glioma cells, an effect that was also ob-
served in tumors that are resistant to TMZ treatment.
However, the GAMG cell line, which was the most sensitive
to both treatments, had an antagonistic response in combina-
torial therapy suggesting that an interaction, worthy of future
investigation may be taking place. In general, we found that
euphol promoted a synergistic antiproliferative effect (chemo-
sensitization), with combined administration of euphol and
TMZ enhancing autophagy. We, therefore, suggest that acti-
vation of autophagy plays a central role in the mechanism of
action of this drug combination.
Concluding, our data provides in vitro and in vivo evidence
that the plant-derived tetracyclic triterpene, euphol, exhibits
potential anti-tumoral effects on glioma. Euphol administra-
tion inhibits proliferation, migration and induces autophagy-
associated cell death in malignant glioma cells. Moreover,
euphol enhances TMZ cytotoxic effects when given in com-
bination and autophagy appears to have an important role,
least in part, in potentiating the therapeutic effect. Our results
provide a new focus for future studies, suggesting euphol as
novel potent antineoplastic agent that also has therapeutic po-
tential for adjuvant cancer treatment.
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